Maternal serum screening for Down's syndrome and neural tube defects;Meternale serumscreening op Down-syndroom en neuralebuisdefecten

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 8, 1998, Pages 409-415

  Van Rijn, M ^a   Christiaens, G C M L ^a   Van Der Schouw, Y T ^b   Hagenaars, A M ^c   De Pater, J M ^d   Visser, G H A ^a  

^a Afd Obstetrie en Gynaecologie   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Klinisch Genetisch Centrum Utrecht

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL;

ADULT; AGING; AMNIOCENTESIS; ARTICLE; CALCULATION; CLINICAL ARTICLE; DOWN SYNDROME; FEMALE; HUMAN; NEURAL TUBE DEFECT; PRENATAL DIAGNOSIS; RISK FACTOR; SCREENING TEST; SPINA BIFIDA; AMNION FLUID; BLOOD; CHEMISTRY; HIGH RISK PREGNANCY; LONGITUDINAL STUDY; MATERNAL AGE; METHODOLOGY; NEWBORN; PREGNANCY; SECOND TRIMESTER PREGNANCY; TWINS;

ALPHA-FETOPROTEINS; AMNIOTIC FLUID; CHORIONIC GONADOTROPIN; DISEASES IN TWINS; DOWN SYNDROME; ESTRIOL; FEMALE; HUMANS; INFANT, NEWBORN; LONGITUDINAL STUDIES; MATERNAL AGE; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY, HIGH-RISK; PRENATAL DIAGNOSIS;

EID: 0032554161     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Werkgroep Prenatale Diagnostiek van de Nederlandse Vereniging voor Obsteirie en Gynaecologie (NVOG) en de Vereniging Klinische Genetica Nederland (VKGN). Jaarverslag 1991-1994. Utrecht: NVOG/VKGN. 1996.
2. Beekhuis JR, Mantingh A, Wolf BTHM de, Lith JMM van, Breed ASPM. Serumscreening van zwangeren op foetale neurale-buisdefecten èn Down-syndroom; eerste ervaringen in Nederland. Ned Tijdschr Geneeskd 1993;137:1303-7.
3. Wald NJ, Cuckle H, Brock JH, Peto R, Polani RE, Woodford FP. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of UK collaborative study on alpha-fetoprotein in relation to neuraltube defects. Lancet 1977;i:1323-32.
4. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926-9.
5. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:686-94.
6. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-30.
7. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95:30-3.
8. Chard T, Lowings C, Kitau MJ. Alphafetoprotein and chorionic gonadotropin levels in relation to Down's syndrome. Lancet 1984; ii:750.
9. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-7.
10. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ 1992;305:391-4.
11. The Royal College of Obstetricians and Gynaecologists (RCOG). Report of the RCOG Working Party on biochemical markers and the detection of Down's syndrome. Londen: RCOG, 1993.
12. Kornman LH, Bcekhuis JR, Mantingh A, Morssink LP. Serum-screening op foetaal Down-syndroom bij zwangeren met een leeftijdsindicatie voor prenatale diagnostiek: minder amniocentesen. Ned Tijdschr Geneeskd 1995;139:1840-4.
13. Palomaki GE, Neveux LM, Haddow JE Can reliable Down's syndrome detection rates be determined from prenatal screening intervention trials? J Med Screen 1996;3:12-7.
14. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkmen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med 1992;327:588-93.
15. Wenstrom KD, Desai R, Owen J, DuBard MB, Boots L. Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old. Am J Obstet Gynecol 1995;173:1287-92.
16. Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol 1993;169:526-30.
17. Philhps OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein. hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992;80(3 Pt 1):353-8.
18. MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol 1991;77:63-8.
19. Reynolds TM, Nix AB, Dunstan FD, Dawson AJ. Age-specific detection and false-positive rates: an aid to counseling in Down syndrome risk screening. Obstet Gynecol 1993;81:447-50.
20. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med 1994;330:1114-8.
21. Piggott M, Wilkinson P, Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. J Med Screen 1994;1:45-9.
22. Mancini G, Perona M, Dall'Amico D, Bollati C, Albano F, Mazzone R, et al. Screening for fetal Down's syndrome with maternal serum markers - an experience in Italy. Prenat Diagn 1991;11:245-52.
23. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fctoprotein. hCG, and unconjugated estriol. Obstet Gynecol 1993; 81:73-7
24. Mooney RA, Peterson O, French CA, Sailer jr DN, Arvan DA. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome. Obstet Gynecol 1994;84:298-303.
25. Kellner LH, Weiss RR, Weiner Z, Neuer M, Martin GM, Schulman H, et al. The advantages of using triple-marker screening for chromosomal abnormalities. Am J Obstet Gynecol 1995;172:831-6.
26. Hook EB, Mutton DE, Ide R, Alberman E, Bobrow M. The natural history of Down syndrome conceptuses diagnosed prenatally that are not electively terminated. Am J Hum Genet 1995;57:875-81.
27. Wildhagen MF, Christiaens GCML, Habbema JDF. Serumscreening bij zwangeren voor Down-syndroom en open neurale-buisdefecten: toetsing aan de Gezondheidsraad-criteria voor genetische screening. Ned Tijdschr Geneeskd 1996;140:85-9.
28. Cuckle HS, Wald NJ. Screening for Down's syndrome. In: Lilford RJ, editor. Prenatal diagnosis and prognosis. Londen: Butterworth, 1990;67-92.
29. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996;16 29-34.
30. Wald N, Cuckle H, Wu TS, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1991;98:905-8.